Analysis Genmab A/S (0MGB)
6/3/2024
Analysis of Genmab A/S (0MGB)
Genmab A/S is a biotechnology company that specializes in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Looking at the recent data provided, we can see that the stock price has been fluctuating within a certain range.Key points from the data:
- The stock price closed at 2110.00000 on the most recent day, with a high of 2115.00000 and a low of 2086.00000.
- The Relative Strength Index (RSI) is at 60.68606, indicating that the stock is neither overbought nor oversold.
- The Moving Average Convergence Divergence (MACD) indicator is negative at -13.37363, with the signal line at -15.20913. The MACD histogram is positive at 1.83550, suggesting a potential bullish signal.
- The Simple Moving Average (SMA) is at 1992.20000, the Exponential Moving Average (EMA) is at 1991.67953, and the Weighted Moving Average (WMA) is at 1985.94839.
Overall, based on the data provided, Genmab A/S seems to be in a relatively stable position with some bullish signals in the MACD histogram. However, investors should consider conducting further analysis and monitoring market trends before making any investment decisions.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and healthy return on assets and equity. The balance sheet shows a current ratio slightly above 1, indicating good liquidity, but a high total debt to equity ratio. The income statement reveals significant revenue and EBITDA, with a positive diluted EPS and net income to common ratio. Quarterly revenue and earnings growth have seen slight declines.
Moving on to stock statistics, the company has a low short ratio and short percent of shares outstanding, with a significant portion held by institutions. The stock price summary shows a beta above 1, with the stock trading within a range between its fifty-two-week low and high.
Valuation metrics indicate a high PEG ratio and price to book ratio, with the stock trading at a relatively high forward and trailing PE. The enterprise value is substantial compared to revenue and EBITDA, with a market capitalization reflecting this.
Lastly, dividends and splits information shows a moderate payout ratio, with both forward and trailing annual dividend rates and yields provided. The company has a history of dividends and stock splits, with upcoming ex-dividend and dividend dates mentioned.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been fluctuating, with a peak in 2020 at $104.9 billion and a slight decrease in 2023 to $169.1 billion.
3. Operating income has shown an overall increasing trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has also been on the rise, with a significant increase from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years, indicating growth in profitability per share.
6. The company has been able to maintain a stable diluted shares outstanding count over the years, which is important for investors to assess the dilution impact on their ownership.
7. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Earnings
The company's results for the most recent quarter, as of April 30, 2025, have not been provided at this time. The previous results from February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were reported after hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on generating positive cash flows from operating activities and making strategic investments and financing decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is higher than the EPS of $1.35 from the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS is projected to be $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This indicates growth compared to the EPS of $5.67 from the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests further growth from the projected EPS for the current fiscal year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the analysts are forecasting moderate to strong sales growth for both the upcoming quarters and the next fiscal year, with an increasing number of analysts providing estimates for the company's performance.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still projected to be healthy.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average forecast at $204.58. The current price of the security is $192.25, which is below the median and average forecast, indicating that the analysts are generally predicting an increase in the price of the security in the future.
MACD of 0MGB
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
